This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 5
  • /
  • MHRA approves Ad26.COV2-S [recombinant] for active...

MHRA approves Ad26.COV2-S [recombinant] for active immunisation against COVID-19 within the United Kingdom - Janssen.

Read time: 1 mins
Published:29th May 2021
Ad26.COV2-S [recombinant] a single-dose coronavirus vaccine from Janssen, part of Johnson & Johnson, has been approved by the MHRA (UK) and is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Ad26.COV2-S [recombinant], has been shown to be 67% effective overall at preventing moderate to severe COVID-19 compared with placebo. The phase III ENSEMBLE trials demonstrated that the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.